Envafolimab real-world safety and effectiveness study
Treatments studied
Part of Cancer clinical trials.
This study looks at how well and how safely Envafolimab (an immunotherapy that helps your immune system fight cancer) works in real life, outside of clinical trials. If you are already receiving Envafolimab under a special access program, your data may help improve cancer care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have received at least one dose of Envafolimab under the Named Patient Program between June 2025 and December 2026.
- You must have a confirmed cancer diagnosis (like a solid tumor with MSI-H or dMMR) for which Envafolimab was prescribed.
- You must have had a disease assessment (e.g., imaging or clinical evaluation) within 8 weeks before your first Envafolimab dose, and at least one assessment after starting it.
- You must have at least 6 months of follow-up data or have documented disease progression or death within that time.
- You must not be participating in any other interventional clinical trial when starting Envafolimab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This study tests whether adding a new immunotherapy drug, envafolimab, to standard chemotherapy and radiation can improve outcomes for patients with locally advanced cervical cancer. You may receive the experimental drug along with your usual treatment, which could help your body fight the cancer more effectively.
This trial tests a new drug, envafolimab, combined with chemotherapy before surgery for patients with a type of bone cancer called osteosarcoma that has not spread. The goal is to see if this approach can improve the chance of removing the tumor successfully and reducing the risk of it coming back.
This trial tests a new immunotherapy drug called envafolimab for people with advanced bile duct or gallbladder cancer. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.